Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InterMune, Inc.
UniQure Looks For Clear Signal From Huntington’s Disease Gene Therapy
After recent landmark approvals in other neurodegenerative diseases such as Alzheimer’s and amyotrophic lateral sclerosis, hopes are rising that Huntington’s disease could be next to reach a breakthrough.
No AdComm Puts Sarepta On Path To Blockbuster Success With Duchenne Gene Therapy
The US FDA’s waiving of an advisory committee is another promising signal that Sarepta's Duchenne gene therapy SRP-9001 could be approved on 29 May and set it up to become a bigger earner than Novartis’s Zolgensma.
Latuda Enters ‘Twilight’ Phase Pending Generic Competition
A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.
Pharma's Clinical Ops Digital Maturity: Patient Experience Tools Lag
Digital maturity of clinical operations at several big pharma firms varies significantly with the gap between best-in-class and the industry average narrowest for site selection tools, recruitment capabilities, and automation, a study has indicated. Digital patient experience tools figure among the least mature capabilities.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.